Section 17-10301. PRESCRIPTION MONITORING DATA REPORTING REQUIREMENTS

 

10301.1 Each dispenser of a covered substance shall submit the prescription monitoring data required in § 10301.4, in the form and manner required by § 10303, to the Program within twenty-four (24) hours after a covered substance is dispensed for each covered substance dispensed.  For purposes of complying with this chapter, dispensing shall not include merely placing the covered substance prescription into a bin for pickup by the ultimate user or his or her agent.

 

10301.2 For purposes of complying with § 10301.1 of this chapter, the Program shall provide dispensers at least ninety (90) days written notice of the date that reporting shall begin. 

 

10301.3 Any dispenser located outside the geographical boundaries of the District that is licensed or registered by the District, shall submit the prescription monitoring data

set forth in § 10301.4 to the Program within twenty-four (24) hours after the covered substance is dispensed to an ultimate user who resides in the District.  The submission shall be in the form and manner required under § 10303.

 

10301.4 Upon dispensing a covered substance, the dispenser of the covered substance shall report the following prescription monitoring data to the Program:

 

(a) Patient full name;

 

(b) Patient address;

 

(c) Patient telephone number;

 

(d) Patient date of birth;

 

(e) Patient gender;

 

(f)Dispenser DEA number, NPI number, or other mutually acceptable identification number;

 

(g) Dispenser name;

(h)Dispenser address;

 

(i)Dispenser telephone number;

 

(j)Prescriber DEA number, NPI number, or other mutually acceptable identification number;

 

(k)Prescriber’s full name;

 

(l)Date prescription was issued by prescriber;

 

(m)Date prescription was dispensed;

 

(n)Prescription number;

 

(o)Prescription type is new or is a refill;

 

(p)Number of refill being dispensed, if applicable;

 

(q)NDC code for the drug dispensed;

 

(r)Quantity dispensed;

 

(s)Days’ supply dispensed;

 

(t)Number of refills ordered;

 

(u)Source of payment for the prescription;

 

(v)Any elements required as a condition of eligibility for a federal grant as outlined in the PDMP Instruction Manual; and

 

(w)Any other information that may be requested by the Director in furtherance of the Program.

 

  10301.5 The reporting requirements of this chapter shall not apply to the dispensing of covered substances when the dispensing is limited to the following:
 
(a)  Administering covered substances;

 
(b)  Dispensing covered substances within an appropriately licensed narcotic maintenance program, such as a methadone treatment program or  substance abuse treatment program;

 
(c)  Dispensing covered substances to inpatients in hospitals or nursing facilities licensed by the Department or facilities that are otherwise  authorized by law to operate as hospitals or nursing homes in the District;

or

 

(d)  Dispensing covered substances to inpatients in hospices licensed or certified by the Department.

 

10301.6 The failure of any person subject to the reporting requirements of this chapter to report the dispensing of a covered substance, unless otherwise exempted under this chapter, or the willful failure to transmit accurate information shall constitute grounds for:

 

(a)  The revocation, suspension, or denial of a District controlled substances registration;

 

(b) Disciplinary action by the relevant health occupations board pursuant to Section 514(c) of the District of Columbia Health Occupations Revision Act of 1985, effective March 25, 1986 (D.C. Law 6-99; D.C. Official Code § 3-1205.14(c)); and

 

(c) The imposition of civil fines pursuant to Section 104 of Department of Consumer and Regulatory Affairs Civil Infractions Act of 1985, effective October 5, 1985 (D.C. Law 6-42; D.C. Official Code § 2-1801.04).

 

10301.7 Each dispenser shall ensure that information reported to the Prescription Drug  Monitoring Program is correct and shall submit corrections when necessary.

 

 

authority

Sections 3 and 11 of the Prescription Drug Monitoring Program Act of 2013, effective February 22, 2014 (D.C. Law 20-66; D.C. Official Code §§ 48-853.02 and 48-853.10 (2014 Repl. & 2015 Supp.)).

source

Final Rulemaking published at 62 DCR 15828 (December 11, 2015).